Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Wednesday, August 24, 2011
Pharmasset receives fast track designation for Hep C drug PSI-938
In March, Pharmasset presented the results of a 14-day study of PSI-938, which revealed strong anti-viral activity and safety and tolerability, both as a stand-alone treatment as well as in combination with the company's PSI-7977, also an inhibitor of viral DNA.